CHOOLIP & SCIENCES Inc
KKRX:2916502,490.00
KRW
-10.00
(-0.40%)
ISIN
KR7291650000
Return %
Stock
S&P 500
1Y
15.28
14.39
3Y
-56.54
81.42
5Y
-86.09
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jib-Hun Jeong
- Full Time Employees
- 44
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Sep 16, 2020
- Website
- aptsci.com
- Similar Companies
- Business
- CHOOLIP & SCIENCES Inc. is a South Korea-based company primarily engaged in the research, development, manufacturing, and distribution of advanced bioscience solutions, healthcare materials, and functional consumer products. Listed on the Korea Exchange under ticker 291650, the company operates across specialized life sciences, bio-health, and performance materials segments, catering to healthcare providers, industrial manufacturers, biotechnology enterprises, and commercial consumer markets. The company provides a comprehensive portfolio of products and technical services organized into core business divisions: biological and healthcare formulations, including specialized dermatological preparations, functional bio-active compounds, cosmeceutical ingredients, and clinical-grade topical solutions; industrial and functional materials, comprising bio-based polymer additives, natural botanical extracts, specialty chemical intermediates, and stabilized active carrier complexes; scientific research and contract development services, covering custom bio-formulation development, raw material assay testing, stability analysis, and pilot-scale manufacturing solutions; and consumer health and wellness goods, featuring branded functional skincare lines, hygiene products, and nutritional supplementary products. CHOOLIP & SCIENCES Inc. utilizes precision processing, proprietary extraction technologies, and standardized quality control systems to supply institutional clients across domestic and international markets in the Asia-Pacific region and North America. In recent developments, CHOOLIP & SCIENCES Inc. has undertaken significant strategic and operational adjustments to accelerate its bio-health and specialty materials commercialization. The company has advanced strategic business reorganizations to optimize its corporate structure, while expanding research and development collaborations with academic institutions and biopharmaceutical partners to enhance its proprietary ingredient pipeline. Concurrently, the company has broadened its commercial footprint through new distribution partnerships in overseas markets, scaled up its domestic manufacturing and analytical testing infrastructure, and introduced next-generation functional formulations targeted at premium cosmeceutical and preventive healthcare sectors. CHOOLIP & SCIENCES Inc. is headquartered in South Korea, where it oversees its primary research laboratories, administrative operations, and production facilities, maintaining an integrated supply network to support its regional and global commercial channels.